A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER

Trial Profile

A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Irinotecan; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms DEEPER
  • Most Recent Events

    • 21 Jan 2017 According to trial design presented at the 2017 Gastrointestinal Cancers Symposium, thirty-three patients have been enrolled as of August 2016.
    • 21 Jan 2017 Trial design presented at the 2017 Gastrointestinal Cancers Symposium
    • 15 Nov 2016 Planned End Date changed from 14 Jul 2021 to 30 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top